Cochrane · systematic review · CD012112
Intravesical Bacillus Calmette‐Guérin with interferon‐alpha versus intravesical Bacillus Calmette‐Guérin for treating non‐muscle‐invasive bladder cancer
Shepherd, ARH, Shepherd, E, Brook, NR · Cochrane Database of Systematic Reviews · 2017 · Cochrane Library
UrologyAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
10
current version
GRADE rated
7
No studies
3
Included studies
NR
No studies 3 · 30%Ungraded 0 · 0%Very low 2 · 20%Low 5 · 50%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Intravesically administered BCG combined with IFN‐α compared to intravesically administered BCG alone for treating non‐muscle‐invasive bladder cancer
Population: patients with non‐muscle invasive bladder cancer
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Recurrence Intravesically administered BCG combined with IFN‐α vs intravesically administered BCG alone | RR 0.76 [0.44, 1.32] | 4 studies · 925 participants | Very low Downgraded: risk of bias, imprecision, inconsistency |
Progression Intravesically administered BCG combined with IFN‐α vs intravesically administered BCG alone | RR 0.26 [0.04, 1.87] | 2 studies · 219 participants | Low Downgraded: risk of bias, imprecision |
Discontinuation of therapy due to adverse events ‐ not measured Intravesically administered BCG combined with IFN‐α vs intravesically administered BCG alone | no estimate extracted | NR | No studies |
Disease‐specific mortality Intravesically administered BCG combined with IFN‐α vs intravesically administered BCG alone | RR 0.38 [0.05, 3.05] | 1 study · 99 participants | Very low Downgraded: risk of bias, imprecision |
Disease‐specific quality of life ‐ not measured Intravesically administered BCG combined with IFN‐α vs intravesically administered BCG alone | no estimate extracted | NR | No studies |
Intravesically administered BCG alternating with IFN‐α compared to intravesically administered BCG alone for treating non‐muscle‐invasive bladder cancer
Population: patients with non‐muscle invasive bladder cancer
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Time‐to‐recurrence Intravesically administered BCG alternating with IFN‐α vs intravesically administered BCG alone | HR 2.86 [1.98, 4.13] | 1 study · 205 participants | Low Downgraded: risk of bias, imprecision |
Time‐to‐progression Intravesically administered BCG alternating with IFN‐α vs intravesically administered BCG alone | HR 2.39 [0.92, 6.21] | 1 study · 205 participants | Low Downgraded: risk of bias, imprecision |
Discontinuation of therapy due to adverse events Intravesically administered BCG alternating with IFN‐α vs intravesically administered BCG alone | RR 2.97 [0.31, 28.09] | 1 study · 205 participants | Low Downgraded: risk of bias, imprecision |
Disease‐specific mortality Intravesically administered BCG alternating with IFN‐α vs intravesically administered BCG alone | HR 2.74 [0.73, 10.28] | 1 study · 205 participants | Low Downgraded: risk of bias, imprecision |
Disease‐specific quality of life ‐ not measured Intravesically administered BCG alternating with IFN‐α vs intravesically administered BCG alone | no estimate extracted | NR | No studies |